By Fineline Cube 
China-based Tcelltech Ltd., a developer of T-cell immunotherapies, has reportedly secured close to USD 40 million in a Series B financing round. The funding was led by CS Capital, with participation from a prominent insurance fund and Lotus Lake Capital. Additional support came from institutions such as China Industrial International Trust Asset Management. The proceeds will be allocated to the clinical development of the company’s core pipeline product, TX-103, in both China and the U.S. The funds will also support the R&D of other pipeline projects, global team expansion, and the acceleration of the company’s international strategic layout and business development (BD) collaborations.
TX-103: B7-H3-Targeted CAR-T Therapy
TX-103, a B7-H3-targeted CAR-T cell therapy, has entered global regulatory clinical studies for solid tumors, including recurrent glioblastoma (rGBM). In early-stage clinical trials, TX-103 demonstrated outstanding efficacy and safety. The therapy significantly prolonged median overall survival (mOS) and improved one-year survival rates in rGBM patients, showcasing a favorable tolerability profile.
Clinical Progress and Future Outlook
The positive results from early-stage trials highlight TX-103’s potential to address significant unmet medical needs in oncology. As Tcelltech advances its clinical development and international expansion, the company aims to establish a strong presence in the global immunotherapy market.-Fineline Info & Tech